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IMPORTANCE Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been
developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only
1 phase 3 randomized clinical trial has demonstrated an overall survival (OS) benefit from
an α-emitting RI, radium 223 (223Ra), vs standard of care. Yet no head-to-head comparison
has been done between α-emitting and β-emitting RIs.
OBJECTIVE To assess OS in menwith bonemetastases from CRPC treated with bone-targeted
RIs and to compare the effects of α-emitting RIs with β-emitting RIs.
DATA SOURCES PubMed, Cochrane Library, ClinicalTrials.gov, andmeeting proceedings
between January 1993 and June 2013 were reviewed. Key terms included randomized trials,
radioisotopes, radiopharmaceuticals, and prostate cancer. Data were collected, checked, and
analyzed from February 2017 to October 2018.
STUDY SELECTION Selected trials included patients with prostate cancer, recruitedmore than
50 patients from January 1993 to June 2013, compared RI use with no RI use (placebo,
external radiotherapy, or chemotherapy), and were randomized. Patients were diagnosed
with histologically proven prostate cancer and disease progression after both surgical or
chemical castration and have evidence of bonemetastasis. Nine randomized clinical trials
were identified as eligible, but 3 were excluded for insufficient data.
DATA EXTRACTION AND SYNTHESIS Individual patient data were requested for each eligible
trial, and all data were checked with a standard procedure. The log-rank test stratified by trial
was used to estimate hazard ratios (HRs), and a similar fixed-effects (FE) model was used to
estimate odds ratios (ORs). The between-trial heterogeneity of treatment effects was
evaluated by Cochran test and I2 and was accounted by a random-effects (RE) model.
MAIN OUTCOMES ANDMEASURES Overall survival; secondary outcomeswere symptomatic
skeletal event (SSE)–free survival and adverse events.
RESULTS Based on 6 randomized clinical trials including 2081 patients, RI use was significantly
associated with OS compared with no RI use (HR, 0.86; 95% CI, 0.77-0.95; P = .004) with
high heterogeneity (χ25 = 24.46; P < .001; I
2 = 80%), but this association disappeared when
using an REmodel (HR, 0.80; 95% CI, 0.61-1.06; P = .12; τ2 = 0.08). The heterogeneity is
explained both by the type of RI and by the inclusion of 2 outlier trials that included 275
patients; the OS benefit was significantly higher with the α-emitting RI 223Ra (HR, 0.70; 95%
CI, 0.58-0.83) but not significant with the β-emitting RI strontium-89 (HR, 0.96; 95% CI,
0.84-1.10) (P for interaction = .004). Excluding the outlier trials led to an overall HR of 0.82
(95% CI, 0.73-0.92; P < .001) (between-trial heterogeneity: χ23 = 6.51; P = .09; I
2 = 54%)
using an FEmodel and an HR of 0.80 (95% CI, 0.65-0.99; P = .04; τ2 = 0.02) using an RE
model. The HR for SSE-free survival was 0.81 (95% CI, 0.69-0.93; P = .004) (between-trial
heterogeneity: χ23 = 6.71; P = .08; I
2 = 55%) when using an FEmodel and was 0.76 (95% CI,
0.58-1.01; P = .06; τ2 = 0.04) when using an REmodel. There were more hematological toxic
effects with RI use compared with no RI use (OR, 1.48; 95% CI, 1.17-1.88; P = .001).
CONCLUSIONS AND RELEVANCE In metastatic CRPC, a significant improvement of OS and
SSE-free survival was obtained with bone-targeted α-emitting but not β-emitting RIs. Caution
is necessary for generalizability of these results, given the between-trial heterogeneity.
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P rostate cancer currently has the highest incidenceand is the second leading cause of cancer death inmen in most western countries.1 Although prostate
cancer is initially sensitive to androgen deprivation, most
deaths result from progression to castration-resistant
prostate cancer (CRPC), with metastases spread usually
involving the bones, and bone metastases are the main
driver of prognosis.2 Docetaxel was the first drug with dem-
onstrated survival advantage in CRPC,3 and since 2010,
androgen receptor pathway inhibitors (abiraterone4 and
enzalutamide5), a chemotherapy agent (cabazitaxel6), and
immunotherapy with sipuleucel-T7 have also been shown to
prolong survival. Until recently, many bone-targeting thera-
pies (zoledronic acid,8 denosumab,9 and radioisotopes
[RIs]10-12) were approved on the basis of pain relief and/or
risk reduction of skeletal complications (skeletal-related
events or symptomatic skeletal events [SSEs]13,14) without
survival benefit. To our knowledge, radium 223 (223Ra), an
α-emitting RI, is the only bone-targeted agent with a clearly
demonstrated overall survival (OS) benefit in men with
CRPC. In the double-blind, phase 3 Alpharadin in Sympto-
matic Prostate Cancer Patients (ALSYMPCA) randomized
clinical trial,15 patients with symptomatic CRPC and bone
metastases randomly received 223Ra or a placebo treatment.
Radium 223 significantly improved OS with a favorable toxic
effect profile.
The main objective of the Meta-analysis of Bone-
Targeting Radiopharmaceutical Therapy in Patients With
Bone Metastases From Prostate Cancer (MORPHEP) was to
evaluate the association of different types of RIs (those emit-
ting α and β radiation) with OS in men with bone metastases
from CRPC. Thus, we aim to study whether the effects of
α-emitting RIs in this setting is only because of their inher-
ent activity or because of differences in study design and
patient selection.
Methods
Protocol and Registration
This meta-analysis was registered on PROSPERO
(CRD42016026842). A collaborative group comprising
researchers involved in the randomizedclinical trials included
in theproject (MORPHEPCollaborativeGroup)wasestablished,
and the meta-analysis was conducted and is reported on its
behalf. We followed the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) reporting
guideline for reporting the results of this meta-analysis.
Study Selection
Selected trials must have (1) included patients with prostate
cancer; (2) recruited more than 50 patients; (3) compared RI
withplacebo,external radiotherapy,orchemotherapy; (4)been
randomized; and (5) completed recruitment between Janu-
ary 1993 and June 2013. Patients must have been diagnosed
with histologically proven prostate cancer and disease pro-
gression after both surgical or chemical castration and have
evidence of bone metastasis.
Search Strategy
Both published and unpublished trials were included in the
meta-analysis.16 To identify as many relevant trials as pos-
sible, systematic searches of several sources were carried out
using electronic database searching for the period of January
1993 to June2013. Searching includedPubMed (eMethods 1 in
the Supplement), the Cochrane Library, handsearching, and
internet searching of review articles, meeting proceedings,
and 1 trials register (ClinicalTrials.gov). The search was up-
datedduring the studyby theMORPHEPCollaborativeGroup.
Data Collection Process andQuality Control
Individual patient data (IPD) were requested for each eligible
trial, includingpatient and tumor characteristics, dates of ran-
domization, SSEs anddeath, treatment armallocation, details
on treatments received, and toxic effects. Follow-up informa-
tionwasupdatedwheneverpossible.When IPDwerenotavail-
able, all efforts were done to collect detailed summary data.
All datawere checkedwith a standardprocedure,17which fol-
lows the recommendations of the Individual Participant Data
Meta-analysis Cochraneworking group. Internal consistency
was checked (eg, chronologyofdates, outlier values), anddata
werecomparedwith trialprotocolsandpublishedreports.Ran-
domizationvaliditywasevaluatedbycheckingpatternsof treat-
mentallocationandbalanceofbaselinecharacteristicsbetween
treatment arms. Follow-up of patientswas also compared be-
tween treatment arms.Data checkingon IPDallowedevaluat-
ing risk of bias in individual trials.
Outcomes
The primary end point was OS, defined as the time from ran-
domization date until death or last follow-up. Secondary end
points were SSE-free survival and toxic effects. Symptomatic
skeletal event–free survivalwas defined as the time from ran-
domization date to the first of symptomatic pathologic bone
fractures, spinal cord compression (SCC), or bone metastasis
forwhich external beam radiotherapy (ERT) or surgical inter-
vention had been performed. Toxic effects included grade 3
and higher hematological toxic effects (hemoglobin, white
blood cells, and platelets), nausea and/or vomiting, and fe-
brile neutropenia. Other criteria listed in theprotocol, such as
Key Points
Question What is the benefit of bone-targeted radioisotope (RI)
use in metastatic castration-resistant prostate cancer, and is there
any difference between α-emitting and β-emitting RIs?
Finding This meta-analysis of individual patient data was based
on 6 randomized clinical trials including 2081 patients that
compared RI use with no RI use study arms with no overall
significant difference. While an α-emitting RI (radium 223) was
significantly associated with higher overall survival and higher
symptomatic skeletal event–free survival, a β-emitting RI
(strontium-89) was not associated with these outcomes.
Meaning Thismeta-analysis suggests a benefit of α-emittingRIs but
not of β-emittingRIs for overall survival and symptomatic skeletal
event–free survival, although caution is necessary for generalizability
of these results, given thebetween-trial heterogeneity.
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pain relief or quality of life, were not analyzed because data
were not homogeneously measured or not available.
Statistical Analysis
Themedian follow-upof each trialwas estimatedusing the re-
verseKaplan-Meiermethod,18andtheoverallmedianfollow-up
was estimated by theweighted (based on sample size) average
of individualmedianfollow-ups.Analyseswerestratifiedbytrial.
Although a 1-stepmeta-analysis of IPDwas initially planned, a
2-stepmeta-analysiswas performed becauseworking directly
ontheIPDwasnotpossibleforalleligibletrials.Fortime-to-event
end points (OS and SSE-free survival), the log-rank expected
numberofeventsandvariancewasused tocalculate individual
andoverall hazard ratios (HRs)of treatmenteffect (RIusevsno
RI use arms)with 95%CIs using a fixed-effects (FE)model.19 A
similarmodelwasused toestimate theodds ratios (ORs) for the
toxiceffectsanalysesafterexcludingstudieswithmorethan20%
missingdata.We imputed the value0.5 if no event occurred in
an arm. For evaluation of between-trial heterogeneity, refer to
eMethods 2 in the Supplement, including theuse of a random-
effects (RE)model.ThePetomethod20wasusedtoestimate the
stratified survival curves comparing the RI use with no RI use
arms. From this, the absolute benefits at 1, 2, andmore than 2
yearswith their 95%CIswere estimated.Weperformedsubset
analysestostudytheassociationoftrial-levelcharacteristics(type
of radiationemittedfromRIandtypeofcomparison)with treat-
ment effect using a test of heterogeneity between thedifferent
groups of trials. We computed residual heterogeneity within
groupsby subtracting the statistic of theheterogeneity test be-
tweengroupsfromthestatisticoftheoverallheterogeneitytest.21
Subgroupanalyses forefficacyendpointsaccording toage,per-
formance status score (0 to 1 vs 2 or greater), serum prostate-
specificantigen(PSA) level,alkalinephosphatase(ALP) level,he-
moglobin level, and number of bonemetastases at baseline (6
or less vs more than 6) were also performed, and we used the
poolingofwithin-trialcovariateinteractionmethod22toestimate
the interactionbetweentreatmenteffectandpatientsubgroups
(eMethods 2 in the Supplement). All analyseswere carried out
by intention to treat, whichmeans that the patients were ana-
lyzedaccordingtothetreatmentallocatedirrespectiveofwhether
theyhadreceivedthat treatmentornot.Unplannedsubset toxic
effects analyseswere performed for hematological and febrile
neutropenia. The P values for testing the treatment effect and
the interactions were calculated from the Wald statistic and
between-trialsheterogeneity test fromtheQ-Cochranstatistic.
These test statistics follow a χ2 distribution. All P values were
2-sided, andaPvalue less than .05wasconsidered statistically
significant.For testsofheterogeneityand interaction, aPvalue
less than .10 was considered significant (eMethods 2 in the
Supplement). Analyses were performed using SAS version 9.4
(SAS Institute).
Results
Study Selection and Characteristics
A total of 9 randomized clinical trials comparing RI use with
noRIusearmsbetweenJanuary 1993andJune2013were iden-
tified as eligible for theMORPHEPmeta-analysis; thePRISMA
flow diagram is shown in eFigure 1 in the Supplement. From
these9eligible trials, IPDordetailed aggregateddatawerenot
available for 3 trials11,23,24 including341patients—2becausewe
could not contact the investigators and 1 because of difficul-
ties to recover data. As a result, 6 trials15,25-29 including 2081
patients (minimum,64patients;maximum,921patients),with
2 large randomized clinical trials (ALSYMPCA trial15 and the
Taxane Radioisotope Zoledronic Acid [TRAPEZE] trial29) rep-
resenting 80%of data, were included (eTable 1 in the Supple-
ment). For the TRAPEZE trial,29 a 2 × 2 randomized trial, all
data comparingRIusewithnoRIuse arms (ratio 1:1)were con-
sidered, ie, includingpatients treatedornotbyzoledronic acid
because there is no known interaction between strontium-89
(Sr89) andzoledronic acid. Two trials15,28 used single 223RaRIs
compared with placebo (n = 985). Three trials25,26,29 tested
Sr89 combined with either chemotherapy or ERT vs chemo-
therapy or ERT alone (n = 893). Among them, 1 chemo-
therapywithSr89combinationstudy25 includedonly respond-
ing or stable patients after an induction chemotherapy
(doxorubicin, vinblastine, ketoconazole, and estramustine).
One trial27 compared Sr89 RI use with ERT (n = 203).
The dose received depended on the type of radioemitter:
theSr89groupsreceivedasingle 150-MBqdose,while the223Ra
groups received 50 kBq/kg every 4weeks for 4 to 6 injections
(eTables 1 and2 in theSupplement). In2 trials,15,28 adhoc sum-
marydatawere available for data checking, efficacy, and toxic
effects analyses, and on request, aggregated data were avail-
able for the subgroup analyses.
The overall median (range) follow-up was 26.7 (0.4-
188.1)months, and themedian (interquartile range) age of pa-
tientswas 70 (64-75) years. Theperformance status scorewas
more than 2 in less than 18%of patients overall (ranging from
less than 10% in the trial by Tu et al25 to approximately 40%
in the trials by Oosterhof et al27 and Smeland et al26) (Table 1)
(eTables 3 and 4 in the Supplement). The proportion of pa-
tients with more than 6 bone metastases ranged from 67.2%
to 85.9% (Table 1). The details of trials’ characteristics are
reported in eTables 3 and 4 in the Supplement.
Risk of BiasWithin Studies
All included trials were validated for adequate randomiza-
tion, blinding, and identical follow-ups between treatment
arms. For details, see eTable 5 in the Supplement.
Treatment Efficacy
Overall, 1495 deaths (71.8%) were observed. In an FE model,
RI use was associated with a significant OS benefit compared
withnoRIuse (HR,0.86;95%CI,0.77-0.95;P = .004),but there
wassignificant (χ25 = 24.46;P < .001)andsubstantial (I2 = 80%)
heterogeneitybetween trials (Figure 1A).AnREmodel showed
no significant treatment effect (HR, 0.80; 95% CI, 0.61-1.06;
P = .12; τ2 = 0.08). The absolute OS differencewas 4.7% (95%
CI, 0.4-9.0) and 3.8% (95%CI, −0.6 to 8.2) at 1 and 2 years, re-
spectively (Figure 2A). When excluding 2 trials25,27 with 95%
CIs thatdidnotoverlap thatof theoverall treatment effect, the
heterogeneity remained significant (χ23 = 6.51;P = .09) butde-
creased tomoderate (I2 = 54%)with similar overall treatment
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effect (FE model: HR, 0.82; 95% CI, 0.73-0.92; P < .001; RE
model:HR, 0.80; 95%CI, 0.65-0.99;P = .04; τ2 = 0.02) (eFig-
ure 2 in the Supplement).
We observed a significant difference of the overall treat-
ment effect between α-emitting RI and β-emitting RI groups
of trials; a significant OS benefit was observed in the α-emit-
ting RI trials (FE model: HR, 0.70; 95% CI, 0.58-0.83; P for
heterogeneity = .47; 2 trials; n = 985), but no significant ben-
efit was seen in the β-emitting RI trials (FE model: HR, 0.96;
95% CI, 0.84-1.10; P for heterogeneity = .001; REmodel: HR,
0.88;95%CI,0.60-1.29; τ2 = 0.11; 4 trials; n = 1096) (χ21 = 8.24;
P for interaction = .004) (Figure 1A). The absolute OS benefit
of RI use in the α-emitter group was 10.4% (95% CI, 3.9-16.9)
at 1 year and9.5%(95%CI, 1.7-17.3) at 2years (Figure2B).There
was no significant OS benefit of β-emitting RI use at 1 year
(absolutedifference,0.0%;95%CI,−5.6 to5.6) and2years (ab-
solutedifference,0.6%;95%CI, −4.8 to6.0) (Figure2C).A sig-
nificant difference was also observed by comparator treat-
ment (eFigure 3 in the Supplement). This subset analysis is
similar to thepreviousonewhen regrouping the4 trials25-27,29
comparing RI use in combination or not with chemotherapy
orERT. These 2 subset analyses didnot explain theoverall be-
tween-trial heterogeneity of treatment effect, since signifi-
cant residual heterogeneity remained (type of radiation:
χ24 = 16.22;P = .003; typeof comparison: χ22 = 9.39;P = .009).
When excluding the trials by Tu et al25 and Oosterhof et al,27
Table 1. Patient Characteristics, Median Follow-up, and Number of Events by Trial and Overall
Characteristica
No. (%)
Oosterhof et al27
(n = 203)
Tu et al25
(n = 72)
Smeland et al26
(n = 64)
Nilsson et al28
(n = 64)
TRAPEZE29
(n = 757)
ALSYMPCA15
(n = 921)
Overall
(N = 2081)
Age, median (IQR), y 70.0
(65.0-75.0)
67.0
(60.2-70.9)
70.9
(63.8-75.9)
72.5
(68.0-78.0)
68.9
(63.9-73.4)
71.0
(64.0-76.0)
70.0
(64.0-75.0)
<70 88 (43.4) 47 (65.3) 30 (46.9) 23 (35.9) 415 (54.8) 395 (42.9) 998 (48.0)
≥70 115 (56.6) 25 (34.7) 34 (53.1) 41 (64.1) 342 (45.2) 526 (57.1) 1083 (52.0)
Performance status score
0-1 122 (60.1) 65 (90.3) 39 (60.9) 53 (82.8) 694 (91.7) 801 (87.0) 1774 (85.2)
≥2 80 (39.4) 7 (9.7) 25 (39.1) 11 (17.2) 63 (8.3) 118 (12.8) 304 (14.6)
Missing 1 (0.5) 0 0 0 0 2 (0.2) 3 (0.1)
Serum PSA level, ng/mL
<143 110 (54.2) 48 (66.7) 36 (56.2) 29 (45.3) 362 (47.8) 433 (47.0) 1018 (48.9)
≥143 86 (42.4) 24 (33.3) 28 (43.8) 35 (54.7) 368 (48.6) 477 (51.8) 1018 (48.9)
Missing 7 (3.4) 0 0 0 27 (3.6) 11 (1.2) 45 (2.2)
Alkaline phosphatase level, U/L
<248.5 83 (40.9) 44 (61.1) 11 (17.2) 31 (48.4) 341 (45.0) 518 (56.2) 1028 (49.4)
≥248.5 110 (54.2) 28 (38.9) 53 (82.8) 33 (51.6) 401 (53.0) 403 (43.8) 1028 (49.4)
Missing 10 (4.9) 0 0 0 15 (2.0) 0 25 (1.2)
Hemoglobin, g/dL
<12.4 102 (50.2) 22 (30.6) 26 (40.6) 24 (37.5) 360 (47.6) 498 (54.1) 1032 (49.6)
≥12.4 91 (44.8) 50 (69.4) 38 (59.4) 40 (62.5) 388 (51.2) 423 (45.9) 1030 (49.5)
Missing 10 (4.9) 0 0 0 9 (1.2) 0 19 (0.9)
No. of bone metastasesb
≤6 65 (32.0) 15 (20.8) 9 (14.1) 19 (29.7) NA 138 (15.0) 246 (18.6)
>6 133 (65.5) 57 (79.2) 55 (85.9) 45 (70.3) NA 779 (84.6) 1069 (80.7)
Missing 5 (2.5) 0 0 0 0 4 (0.4) 9 (0.7)
Duration of follow-up,
median (range), mo
62.7
(1.8-62.7)
22.3
(1.0-32.3)
NA
(2.6-188.1)
12.1
(0.5-25.6)
39.2
(0.4-75.1)
10.0
(0.4-36.6)
26.7
(0.4-188.1)
No. of deaths 194 (95.6) 41 (56.9) 64 (100) 50 (78.1) 618 (81.6) 528 (57.3) 1495 (71.8)
No. of symptomatic
skeletal events
NA NA 20 (31.3) 33 (51.6) 396 (52.3) 318 (34.5) 767 (42.5)
Spinal cord compression NA NA 4 (6.3) 5 (7.8) 58 (7.7) 23 (2.5) 90 (5.0)
Pathologic bone fracture NA NA 0 2 (3.1) 25 (3.3) 34 (3.7) 60 (3.4)
Surgical intervention NA NA 0 0 1 (0.1) 2 (0.2) 3 (0.2)
External radiotherapyc NA NA 16 (25.0) 26 (40.6) 312 (41.2) 259 (28.1) 613 (33.9)
Abbreviations: ALSYMPCA, Alpharadin in Symptomatic Prostate Cancer
Patients; IQR, interquartile range; NA, not applicable; PSA, prostate-specific
antigen; TRAPEZE, Taxane Radioisotope Zoledronic Acid.
SI conversion factors: To convert PSA tomicrograms per liter, multiply by 1; to
convert alkaline phosphatase to microkatals per liter, multiply by 0.0167; to
convert hemoglobin to grams per liter, multiply by 10.
a Continuous characteristics were divided into 2 classes using themedian.
b For the trial by Nilsson et al28 and the ALSYMPCA trial,15 superscan was
considered as higher than 6 bonemetastases. For the TRAPEZE trial,29
NA indicates that the number of bonemetastases at baseline was not
collected or available in this trial.
c This category contains both external beam radiotherapy and use of
radioisotope for the TRAPEZE trial.29
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the type of RI explained the observed heterogeneity between
trials, since the residual heterogeneity was close to 0with an
HR of 0.93 (95% CI, 0.80-1.08) for β-emitting RIs, which re-
mained nonsignificant (eFigure 2 in the Supplement). The
difference in type of emitter may be confounded by the
timingof the interventions (before vs afterDocetaxel era) and
the type of control arm.
Planned subgroupanalyses (Figure 1B) excluding the trials
byTuet al25 andOosterhof et al27 showeda significant interac-
tion between treatment effect and serum PSA level (HR, 1.39;
Figure 1. Overall Survival and Subgroup Analysis of Trials Comparing Patients Receiving Radioisotopes (RIs)
With Patients Receiving No RIs by Type of Radiation
0.2 3
HR (95% CI)
1
Favors
RI Use
Favors
No RI UseSource
α-Emitting RIs
Nilsson et al,28 2007
ALSYMPCA15
Subtotal
Subtotal
Total
β-Emitting RIs
Oosterhof et al,27 2003
TRAPEZE29
Tu et al,25 2001
Test for heterogeneity: χ2 = 24.46; P <.001; I 2 = 80%
Residual heterogeneity: χ2 = 16.22; P = .003
RE effect: P = .004
RE model: HR, 0.80; 95% CI, 0.61-1.06; P = .12; τ2 = 0.08
Test for interaction: χ2 = 8.24; P = .004
P Value
.47a
0b
.001a
0.11b
Smeland et al,26 2003
No. of Deaths/No. Entered
23/33
333/614
356/647
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14/36
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449/545
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RI
30/30
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27/36
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468/551
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27/31
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34/34
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–37.6
–44.2
13.7
–10.4
–12.3
–9.0
–53.2
O – E
0
11.9
110.0
121.9
47.0
9.8
153.1
225.3
347.2
Variance
15.5
0.57 (0.33-1.01)
0.71 (0.59-0.86)
FE: 0.70 (0.58-0.83)
RE: 0.70 (0.58-0.83)
1.34 (1.01-1.78)
0.34 (0.18-0.65)
1.00 (0.61-1.64)
0.92 (0.79-1.08)
FE: 0.96 (0.84-1.10)
RE: 0.88 (0.60-1.29)
0.86 (0.77-0.95)
HR (95% CI)
Overall survival analysisA
0.35 2
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P for Between-Trial
Heterogeneity of
Interaction
.44
.01
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.53
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Performance status score
0-1
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Alkaline phosphatase level, U/L
<248.5
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Hemoglobin level, g/dL
<12.4
≥12.4
No. of bone metastasesd
≤6
>6
No. of Deaths/No. Entered
323/497
371/558
RI
594/929
100/125
273/508
404/524
296/537
390/508
398/530
292/519
35/117
351/557
280/385
286/366
No RI
80/92
485/658
305/384
247/352
329/382
233/364
263/370
301/378
234/322
21/49
–31.3
–27.7
O – E
–51.6
–5.2
–42.8
–7.2
–12.6
–57.5
–19.4
–37.3
–1.8
–42.8
148.7
154.5
Variance
260.8
42.5
124.2
169.6
126.0
173.8
166.2
134.4
12.5
136.0
0.81 (0.69-0.95)
0.84 (0.71-0.98)
0.82 (0.73-0.93)
0.89 (0.66-1.20)
0.71 (0.59-0.84)
0.96 (0.82-1.11)
0.90 (0.76-1.08)
0.72 (0.62-0.83)
0.89 (0.76-1.04)
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P for Interaction
Subgroup analysis of overall survivalcB
5
4
1
A, Overall survival in all trials. τ2 values were estimated using the DerSimonian
and Laird method.23 Test for heterogeneity: α-emitting RIs: χ21 = 0.53; P = .47;
I2 = 0%; β-emitting RIs: χ23 = 15.67; P < .001; I2 = 81%. B, Subgroup analysis of
OS. ALSYMPCA indicates Alpharadin in Symptomatic Prostate Cancer Patients;
FE, fixed-effects model; HR, hazard ratio; O − E, observedminus expected
number of deaths in the experimental arm; PSA, prostate-specific antigen;
RE, random-effects model; and RI, radioisotope. To convert PSA tomicrograms
per liter, multiply by 1; to convert alkaline phosphatase to microkatals per liter,
multiply by 0.0167; to convert hemoglobin to grams per liter, multiply by 10.
a P value corresponds to the test for between-trial heterogeneity.
b τ2.
c The trials by Tu et al25 and Oosterhof et al27 were excluded because they were
considered outliers.
dData from the Taxane Radioisotope Zoledronic Acid (TRAPEZE) trial29 were
not included in the subgroup analysis of bonemetastases at baseline because
this information was not available.
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95%CI, 1.10-1.75;P for interaction = .01)andbetweentreatment
effect andALP level (HR,0.78;95%CI,0.62-0.98;P for interac-
tion = .04)butwithheterogeneityof trial interactions.Whenan
REmodelwasused,onlythe interactionbetweentreatmentand
serumPSA level remainedstatistically significantat 10%(HRof
interaction, 1.63;95%CI,0.92-2.89;P = .09) (eMethods2 in the
Supplement); patients with a lower serumPSA level (less than
143ng/mL[toconvert tomicrogramsper liter,multiplyby1]) (FE
model:HR,0.71;95%CI,0.59-0.84)hadabetterbenefitofRIuse
comparedwithpatientswithahigherserumPSAlevel(FEmodel:
HR, 0.96; 95%CI, 0.82-1.11) (eFigure 4 in the Supplement). Af-
terexcludingthetrialbyNilssonetal28becauseofbetween-trial
heterogeneitywithinaclass (eFigure4 in theSupplement), this
interactionremainedstatistically significant (HRof interaction,
1.29;95%CI, 1.02-1.64;P = .03)withnobetween-trialheteroge-
neity and homogeneous overall treatment effect in each class.
Figure2. StratifiedSurvivalCurves forOverall Survival (OS)andSymptomatic Skeletal Event (SSE)–FreeSurvivala
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No significant interaction between treatment effect and other
patients’ characteristicswasobserved (Figure 1B), including the
unplannedanalysisofALP levelwith thecutoffof 120U/L (data
notshown;toconverttomicrokatalsperliter,multiplyby0.0167).
For SSE-free survival, data were available from 4
trials15,26,28,29 including 1806patients,with767SSEs (90SCCs,
61 pathologic bone fractures, 3 surgical interventions, and613
ERTs).No informationwas collected for theTuet al.25The trial
by Oosterhof et al27 was also excluded from this analysis
since SSEs were not collected systematically. In the trial by
Smelandet al,26 only SCCandERTdatawere collected. In con-
trastwith the trial byNilssonet al28 and theALSYMPCA trial,15
the TRAPEZE trial29 did not distinguish between ERT and
the reuse of RI, and thus these men (111 of 314 [35.4%]) were
considered inonly 1 category.ComparedwithnoRIuse,RIuse
had a significant benefit on SSE-free survival (FEmodel: HR,
0.81; 95% CI, 0.69-0.93; P = .004) (between-trial heteroge-
neity: χ23 = 6.71; P = .08; I2 = 55%) (Figure 3A), which disap-
pearedwithanREmodel (HR,0.76; 95%CI,0.58-1.01;P = .06;
τ2 = 0.04). Theabsolute SSE-free survival differencewas6.6%
(95% CI, 1.3-11.9) at 1 year and 3.8% (95% CI, −3.2 to 10.8) at
2 years (Figure 2D).
The interaction between emitter type and treatment ef-
fectonSSE-freesurvivalwassignificant (χ21 = 5.26;P = .02)with
no significant residual heterogeneity (χ22 = 1.45; P = .48)
(Figure 3A). The risk reduction of SSE was restricted to the
α-emitting RI trials (FE model: HR, 0.65; 95% CI, 0.52-0.82;
P for heterogeneity = .67; 2 trials; n = 985). In terms of SSE-
freerates, thedifferenceswere12.9%(95%CI,5.0-20.8;)at1year
and −1.2% (95% CI, −15.1 to 12.7) at 2 years (Figure 2E). Use of
β-emitting RIs was not significantly associated with SSE-free
survival (FE model: HR, 0.93; 95% CI, 0.77-1.13; P for hetero-
geneity = .26; 2 trials; n = 821), with absolute differences of
1.2%(95%CI,−5.7 to8.1) at 1yearand2.9%(95%CI,−5.5 to 11.3)
at2years (Figure2F).Asignificant interactionbetweenthetype
ofcomparisonandthetreatmenteffectwasobserved(χ22 = 6.54;
P = .04) (eFigure 5 in the Supplement).
Plannedsubgroupanalyses forSSE-freesurvival (Figure3B)
showeda significant interactionbetween treatment effect and
serum PSA level (HR of interaction, 1.33; 95% CI, 1.00-1.79;
P = .05), which disappeared after taking into account signifi-
cantheterogeneity (χ23 = 8.12;P = .04)byanREmodel (HR, 1.51;
95% CI, 0.81-2.82; P = .19), and a significant interaction be-
tween treatment effect andALP level (HRof interaction, 1.34;
95% CI, 1.00-1.80; P = .05), with no between-trial heteroge-
neity of interaction (χ23 = 4.80; P = .19); patients with a lower
ALP level (HR, 0.69; 95% CI, 0.56-0.85) had a better benefit
whenusingRIs comparedwithpatientswithahigherALP level
(HR, 0.94; 95%CI, 0.77-1.16) (eFigure 6A in the Supplement).
This interaction remained significant (χ21 = 2.99;P = .08),with
homogeneous treatmenteffect ineachclassafterexcluding the
trials by Smeland et al26 andNilsson et al,28 2 trials with large
interaction effects (eFigure 6B in the Supplement).No signifi-
cant interaction between treatment effect andpatients’ other
characteristics was observed (Figure 3B), including the
unplanned analysis of ALP level using the cutoff of 120 U/L
(data not shown). As suggested by a reviewer, we performed
an unplanned sensitivity analysis including only patients not
treated with zoledronic acid from the TRAPEZE trial29 in the
meta-analysis (eMethods 3 in the Supplement).
Adverse Events
Therateofseverehematological toxiceffects increasedwiththe
useofRI(20.5%)comparedwithnoRIuse(15.9%)(OR,1.48;95%
CI, 1.17-1.88;P = .001) (Table 2) (eTable 6 and eFigure 7A in the
Supplement).Hematologicaltoxiceffectsbetweentheα-emitting
RIgroup(OR,1.77;95%CI,1.24-2.54)andtheβ-emittingRIgroup
(OR,1.29;95%CI,0.94-1.77) (eFigure7B intheSupplement)was
not significantly different (P for interaction = .19) (unplanned
analysis).Therateofnauseaand/orvomitingwasnotsignificantly
different between theRIuse andnoRIuse arms (OR, 1.27; 95%
CI,0.74-2.17;P = .39) (eFigure8 in theSupplement),norwas the
rateof febrileneutropenia (OR, 1.00;95%CI,0.59-1.68;P = .99)
(eFigure 9A in the Supplement). The unplanned analysis of
febrileneutropenia ratesaccordingtothetypeof radiationemit-
ted revealed no significant difference between the RI effect in
the α-emitter group (OR, 0.60; 95% CI, 0.06-6.36) and in the
β-emitter group (OR, 1.02; 95%CI, 0.60-1.75) (P for interaction
= .67), with only 2 events observed in the α-emitting RI group
(eFigure 9B in the Supplement).
Discussion
Bone is the main target of prostate cancer dissemination and
a source of major morbidity and mortality.30,31 The present
meta-analysis based on IPD from randomized clinical trials
shows thatRIdoesnot improveOS inmenwithCRPCandbone
metastases. However, an OS benefit was observed with the
223Ra α-emitting RI, while no significant benefit was ob-
servedwith the Sr89 β-emitting RI. In the subgroup analyses,
menwith the lowest serumPSAvaluesappeared tobenefit sig-
nificantlymore frombone-targetedRI therapycomparedwith
those with the highest serum PSA values. No significant in-
teraction was found between treatment effect and age, per-
formance status score, ALP level, hemoglobin level, and the
number of bonemetastases at baseline. Furthermore, similar
results were observed for SSE-free survival except when ex-
cluding patients treatedwith zoledronic acid in the TRAPEZE
trial,29 where we observed a significant overall benefit of RI
use both in the FE and REmodels (eMethods 3 in the Supple-
ment). Anoverall risk reductionof SSE-free survivalwasmore
important in patients with low ALP levels comparedwith pa-
tients with high ALP levels. Hematological toxic effects were
more frequently observed in patients treated by RI compared
with those treatedwithout RI,with no significant differences
according to the type of radiation.
In the recently reported interim analysis of the Eastern
CooperativeOncologyGroup (ERA223) study32 including401
and405patients in the 223Rawith abirateroneacetate andpla-
cebo with abiraterone acetate arms, respectively, concurrent
treatment with 223Ra and abiraterone acetate did not im-
prove SSE-free survival (HR, 1.12; 95% CI, 0.92-1.37) and OS
(HR, 1.21; 95% CI, 0.95-1.51). These results differ from the
ALSYMPCA trial.15 One of the explanations of the failure of
223Rawhen it is associatedwith abiraterone is probably owing
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to the biological activities of bothdrugs. In fact,weknow that
abiraterone acetate promotes the osteoblastic activity in the
bone and that 223Ra is themost active in the bone remodeling
sites. Likely, thismakes the 223Raharmfulby targetingnotonly
metastatic bones but also disease-free bones. As this trialwas
not included in our study because the recruitment was more
recent, an unplanned post hoc analysis including ERA 223
trial32 data based on summary datawas carried out for OS but
not for SSE-free survival, since death was considered as an
event in the ERA 223 trial, contrary to our meta-analysis
(eMethods 4 in the Supplement).
Furthermore, theuseof theβ-emittingRISr89wasnot sig-
nificantlyassociatedwithOSbothwhenusedaloneand incom-
bination, which is consistent with earlier reported data.10,29
Figure 3. Symptomatic Skeletal Event (SSE)–Free Survival and Subgroup Analyses of Trials Comparing Patients Receiving Radioisotopes (RIs)
With Patients Receiving No RIs by Type of Radiation
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A, Symptomatic skeletal event–free survival excluding 2 trials.25,27 τ2 values
were estimated using the DerSimonian and Laird method.23 Test for
heterogeneity: α-emitting RIs: χ21 = 0.18; P = .67; I2 = 0%; β-emitting RIs:
χ21 = 1.28; P = .26; I2 = 22%. B, Subgroup analysis of SSE-free survival.
ALSYMPCA indicates Alpharadin in Symptomatic Prostate Cancer Patients;
FE, fixed-effects model; HR, hazard ratio; O − E, observedminus expected
number of SSEs in the experimental arm; PSA, prostate-specific antigen;
RE, random-effects model; and RI, radioisotope. To convert PSA tomicrograms
per liter, multiply by 1; to convert alkaline phosphatase to microkatals per liter,
multiply by 0.0167; to convert hemoglobin to grams per liter, multiply by 10.
a P value corresponds to the test for between-trial heterogeneity.
b τ2.
c The trials by Tu et al25 and Oosterhof et al27 were excluded because
no information was available for the former and data were not reliable
for the latter.
dData from the Taxane Radioisotope Zoledronic Acid (TRAPEZE) trial29 were
not included in the subgroup analysis of bonemetastases at baseline because
this information was not requested in this trial.
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Only 1 study using a β-emitting RI, the trial by Tu et al,25 re-
ported OS and SSE-free survival improvements. In this trial,
Sr89 was used as a maintenance strategy in men selected for
having a chemosensitive cancer. No improvement in time to
SSEwasobservedwithβ-emittingRIs.Most likely,physical and
biological properties explain the superiority of α-emittingRIs
over β-emitting RIs in men with CRPC.33
Strengths and Limitations
Themainstrengthof thismeta-analysis is theuseof IPD,which
alloweddetailed checking of each trial thatwas subsequently
reanalyzed and validated by the trialists. The intention-to-
treat principle was respected for all analyses, and subgroup
analyses have been performed through the estimation of
interaction terms.
Thismeta-analysis has limitations. First, data from3 ran-
domized clinical trials could not be retrieved, and therefore,
thismeta-analysiswas limited to 6 randomized clinical trials,
with 2 major trials (the ALSYMPCA and TRAPEZE trials15,29)
providing more than 80% of data. This first limit has no ef-
fect on the main findings (eMethods 5 in the Supplement).
When using an RE approach, used in particular in case of
between-trial heterogeneity, the relative weight of the
ALSYMPCA and TRAPEZE trials compared with an FE ap-
proach was 21.8% and 22.5% instead of 30.9% and 44.8%,
respectively. Second, substantial and moderate heteroge-
neity was observed between trials for OS and SSE-free sur-
vival analyses, respectively, leading to a nonsignificant effect
when using an RE model. For OS, this between-trial hetero-
geneity is mainly explained by 2 outliers (with I2 decreasing
from 80% to 54%) and by the type of emitted radiations. The
2 outliers correspond to (1) the large treatment effect re-
ported in the trial byTuet al,25whichmaybe explainedby the
selected population—men with a cancer response or stabili-
zation after induction chemotherapy—and (2) the significant
negative effect of Sr89 compared with pain treatment with
local field radiotherapyreported in the trialbyOosterhofetal,27
whichwas difficult to explain by the authors. One hypothesis
is that Sr89 was given to patients with more impaired global
health. When excluding these 2 trials, a similar and signifi-
cant treatment effect was observed both for the FE and RE
models. For SSE-free survival, for which the analysis is lim-
ited to 4 trials only, since the 2 trials had no available infor-
mation, themoderate trial heterogeneity is related to the type
of emitted radiations. Themethods ofDerSimonian andLaird
that we used for the estimation of the between-trial variabil-
ity with the RE model are criticized by some authors.34 Its
estimation by a restricted maximum likelihood method
gives similar results in thismeta-analysis except for themain
analysis (τ2 value: restricted maximum likelihood, 0.14;
DerSimonianandLaird,0.08).The residualheterogeneitymay
be explained by patient characteristics. The trials’ accrual
period, which ranged from 1993 to 2013, might have added
heterogeneity in theresults.Thesubsetanalysisbytypeofcom-
parison is limited owing to the number of trials and is re-
duced to the subset analysis by typeof emitted radiationwhen
excluding the2outliers.A further limitationconcerns thequal-
ity of data collected for the SSE-free survival analysis and the
lack of power for the subset analyses of toxic effects.
Conclusions
This meta-analysis supports the role of α-emitting RIs (223Ra)
asa treatment formenwithCRPCandbonemetastasesboth for
OS and the prevention of SSEs but not of β-emittingRIs (Sr89).
The action of α-emitting RIs may be explained by their physi-
cal properties irrespective of the studydesign.However, these
results must be interpreted with caution because of the ob-
served between-trial heterogeneity. Furthermore, dedicated
studies are needed to identify biomarkers of response to 223Ra
and to define the best and safest combinations.
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